|
|
Volumn 168, Issue 4, 2017, Pages 564-565
|
|
Where is the Future of Drug Discovery for Cancer?
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABC TRANSPORTER;
ANDROGEN RECEPTOR;
B RAF KINASE;
ESTROGEN RECEPTOR;
MONOCLONAL ANTIBODY;
MYC PROTEIN;
PIK3CA PROTEIN;
PROTEASOME;
PROTEIN;
PROTEIN BCL 2;
PROTEOME;
UBIQUITIN;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC AGENT;
ANTIBODY AFFINITY;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER THERAPY;
CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT;
COMPLEX FORMATION;
DRUG DEVELOPMENT;
EPIGENETICS;
GENE EXPRESSION;
HISTONE CODE;
HUMAN;
IMMUNOCOMPETENT CELL;
MALIGNANT NEOPLASM;
MASS SPECTROMETRY;
METABOLISM;
NOTE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEOMICS;
RNA SPLICING;
RNA TRANSLATION;
SCIENTIST;
TUMOR MICROENVIRONMENT;
CHEMISTRY;
INTERVIEW;
MOLECULARLY TARGETED THERAPY;
NEOPLASMS;
PATHOLOGY;
ANTINEOPLASTIC AGENTS;
DRUG DISCOVERY;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
|
|
EID: 85012072401
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2017.01.032 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|